1. 1404PSafety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. (23rd October 2018) Authors: Morelli, A M; Migliorino, M R; Morabito, A; Chiari, R; Grossi, F; Bordi, P; Di Costanzo, F; Delmonte, A; Romano, G; Misino, A; Scotti, V; Gregorc, V; Pisconti, S; Ceresoli, G L; Del Conte, A; Colantonio, I; Ciuffreda, L; Capelletto, E; Stura, I; Novello, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 78P A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM). (15th December 2019) Authors: Tagliamento, M; Bironzo, P; De Luca, E; Pignataro, D; Rapetti, S G; Audisio, M; Bertaglia, V; Paratore, C; Bungaro, M; Olmetto, E; Artusio, E; Reale, M L; Zichi, C; Capelletto, E; Carnio, S; Buffoni, L; Passiglia, F; Novello, S; Di Maio, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗